Translational PK-PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576

Roberta Bursi, Gul Erdemli, Robert Campbell, Matthew M Hutmacher, Thomas Kerbusch, David C Spanswick, Ross Jeggo, Kari R Nations, Peter Dogterom, Jacques Schipper, Mohammed Shahid

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)

Abstract

INTRODUCTION: The alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor potentiator Org 26576 represents an interesting pharmacological tool to evaluate the utility of glutamatergic enhancement towards the treatment of psychiatric disorders. In this study, a rat-human translational pharmacokinetic-pharmacodynamic (PK-PD) model of AMPA receptor modulation was used to predict human target engagement and inform dose selection in efficacy clinical trials. METHODS: Modelling and simulation was applied to rat plasma and cerebrospinal fluid (CSF) pharmacokinetic and pharmacodynamic measurements to identify a target concentration (EC(80)) for AMPA receptor modulation. Human plasma pharmacokinetics was determined from 33 healthy volunteers and eight major depressive disorder patients. From four out of these eight patients, CSF PK was also determined. Simulations of human CSF levels were performed for several doses of Org 26576. RESULTS: Org 26576 (0.1-10 mg/kg, i.v.) potentiated rat hippocampal AMPA receptor responses in an exposure-dependant manner. The rat plasma and CSF PK data were fitted by one-compartment model each. The rat CSF PK-PD model yielded an EC(80) value of 593 ng/ml (90 confidence interval 406.8, 1,264.1). The human plasma and CSF PK data were simultaneously well described by a two-compartment model. Simulations showed that in humans at 100 mg QD, CSF levels of Org 26576 would exceed the EC(80) target concentration for about 2 h and that 400 mg BID would engage AMPA receptors for 24 h. CONCLUSION: The modelling approach provided useful insight on the likely human dose-molecular target engagement relationship for Org 26576. Based on the current analysis, 100 and 400 mg BID would be suitable to provide phasic and continuous AMPA receptor engagement, respectively.
Original languageEnglish
Pages (from-to)713 - 724
Number of pages12
JournalPsychopharmacology
Volume218
Issue number4
DOIs
Publication statusPublished - 2011
Externally publishedYes

Cite this